Zokinvy approved to treat ultra-rare paediatric diseases in Japan
Zokinvy is indicated for Hutchinson-Gilford progeria syndrome (HGPS) and processing deficient progeroid laminopathy (PDPL), two ultra-rare paediatric diseases…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
19 Jan 24
Zokinvy is indicated for Hutchinson-Gilford progeria syndrome (HGPS) and processing deficient progeroid laminopathy (PDPL), two ultra-rare paediatric diseases…
17 Jan 24
The approval was based on results from the Phase IB/III IMscin001 study which showed the SC formulation showed…
09 Jan 24
EU health regulator has approved the combination for adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom…
22 Dec 23
The ligand-conjugated antisense oligonucleotide, which is specifically designed to decrease the production of the transthyretin protein, was approved…
21 Dec 23
The regular approval from the US regulator pertains to the use of the B-cell immunomodulator to mitigate the…
20 Dec 23
V116, which is intended to be administered as a single dose, is designed to specifically mitigate the risk…
19 Dec 23
Manufactured from pooled human plasma from American donors, Alyglo is a liquid solution with 10% immunoglobulin G (100…
18 Dec 23
The approval was based on the findings from the Phase 3 EV-302 in which the combination nearly doubled…
18 Dec 23
According to Arcutis Biotherapeutics, ZORYVE foam provides swift disease clearance and substantial itch reduction and is the first…
15 Dec 23
The approval is based on the results of a multi-site, single-arm, externally controlled trial in which the addition…